Editing Misconceptions about HIV/AIDS (section)

====High usage of clotting factor concentrate, not HIV, leads to CD4+ T-cell depletion and AIDS in hemophiliacs====
This view is contradicted by many studies. For example, among HIV-seronegative patients with [[hemophilia A]] enrolled in the Transfusion Safety Study, no significant differences in CD4+ T-cell counts were noted between 79 patients with no or minimal factor treatment and 52 with the largest amount of lifetime treatments. Patients in both groups had CD4+ T-cell-counts within the normal range.<ref name="Hasset, 1993">{{cite journal | last1 = Hassett | first1 = J. | last2 = Gjerset | first2 = G.F. | last3 = Mosley | first3 = J.W. | last4 = Fletcher | first4 = M.A. | last5 = Donegan | first5 = E. | last6 = Parker | first6 = J.W. | last7 = Counts | first7 = R.B. | last8 = Aledort | first8 = L.M. | last9 = Lee | first9 = H. |display-authors=etal | year = 1993 | title = Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group | journal = Blood | volume = 82 | issue = 4| pages = 1351–57 | pmid = 8353293  | doi = 10.1182/blood.V82.4.1351.1351 | doi-access = free }}</ref> In another report from the Transfusion Safety Study, no instances of AIDS-defining illnesses were seen among 402 HIV-seronegative hemophiliacs who had received factortherapy.<ref name="Aledort, 1993">{{cite journal | last1 = Aledort | first1 = L.M. | last2 = Operskalski | first2 = E.A. | last3 = Dietrich | first3 = S.L. | last4 = Koerper | first4 = M.A. | last5 = Gjerset | first5 = G.F. | last6 = Lusher | first6 = J.M. | last7 = Lian | first7 = E.C. | last8 = Mosley | first8 = J.W. | year = 1993 | title = Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group | journal = N. Engl. J. Med. | volume = 328 | issue = 6| pages = 441–42 | pmid = 8093638 | doi = 10.1056/NEJM199302113280614 | doi-access = free }}</ref>

In a cohort in the [[United Kingdom]], researchers matched 17 HIV-seropositive [[hemophiliac]]s with 17 HIV-seronegative hemophiliacs with regard to clotting factor concentrate usage over a ten-year period. During this time, 16 AIDS-defining clinical events occurred in 9 patients, all of whom were HIV-seropositive. No AIDS-defining illnesses occurred among the HIV-negative patients. In each pair, the mean CD4+ T-cell count during follow-up was, on average, 500 cells/μL lower in the HIV-seropositive patient.<ref name="Sabin, 1996">{{cite journal | last1 = Sabin | first1 = C.A. | last2 = Pasi | first2 = K.J. | last3 = Phillips | first3 = A.N. | last4 = Lilley | first4 = P. | last5 = Bofill | first5 = M. | last6 = Lee | first6 = C.A. | year = 1996 | title = Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A | journal = BMJ | volume = 312 | issue = 7025| pages = 207–10 | pmid = 8563582 | pmc = 2349998 | doi=10.1136/bmj.312.7025.207}}</ref>

Among HIV-infected hemophiliacs, Transfusion Safety Study investigators found that neither the purity nor the amount of factor VIII therapy had a deleterious effect on CD4+ T-cell counts.<ref name="Gjerset, 1994">{{cite journal | last1 = Gjerset | first1 = G.F. | last2 = Pike | first2 = M.C. | last3 = Mosley | first3 = J.W. | last4 = Hassett | first4 = J. | last5 = Fletcher | first5 = M.A. | last6 = Donegan | first6 = E. | last7 = Parker | first7 = J.W. | last8 = Counts | first8 = R.B. | last9 = Zhou | first9 = Y. |display-authors=etal | year = 1994 | title = Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group | journal = Blood | volume = 84 | issue = 5| pages = 1666–71 | pmid = 7915149  | doi = 10.1182/blood.V84.5.1666.1666 | doi-access = free }}</ref> Similarly, the Multicenter Hemophilia Cohort Study found no association between the cumulative dose of plasma concentrate and incidence of AIDS among HIV-infected hemophiliacs.<ref name="Goedert, 1989">{{cite journal | last1 = Goedert | first1 = JJ | last2 = Kessler | first2 = CM | last3 = Aledort | first3 = LM | last4 = Biggar | first4 = RJ | last5 = Andes | first5 = WA | last6 = White Gc | first6 = 2nd | last7 = Drummond | first7 = JE | last8 = Vaidya | first8 = K | last9 = Mann | first9 = DL | last10 = Eyster | first10 = M. Elaine | last11 = Ragni | first11 = Margaret V. | last12 = Lederman | first12 = Michael M. | last13 = Cohen | first13 = Alan R. | last14 = Bray | first14 = Gordon L. | last15 = Rosenberg | first15 = Philip S. | last16 = Friedman | first16 = Robert M. | last17 = Hilgartner | first17 = Margaret W. | last18 = Blattner | first18 = William A. | last19 = Kroner | first19 = Barbara | last20 = Gail | first20 = Mitchell H. | title = A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia | journal = The New England Journal of Medicine | volume = 321 | issue = 17 | pages = 1141–48 | year = 1989 | pmid = 2477702 | doi = 10.1056/NEJM198910263211701 | display-authors = 8 }}</ref>